BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feng D, Sun J. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma. Scand J Immunol 2020;92:e12910. [PMID: 32471019 DOI: 10.1111/sji.12910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Firer MA, Luboshits G. Antibody‐Drug‐Conjugate Therapy for Hematological Cancers: Matching Cell Biology with Clinical Benefit. Adv Funct Mater 2021;31:2100032. [DOI: 10.1002/adfm.202100032] [Reference Citation Analysis]
2 Uckun FM. Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma. Cancers (Basel) 2021;13:2018. [PMID: 33922005 DOI: 10.3390/cancers13092018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Zhang H, Liu M, Xiao X, Lv H, Jiang Y, Li X, Yuan T, Zhao M. A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2022;:1-10. [PMID: 35105265 DOI: 10.1080/10428194.2022.2030476] [Reference Citation Analysis]
4 Wang L, Qian J, Yang Y, Gu C. Novel insights into the impact of the SUMOylation pathway in hematological malignancies (Review). Int J Oncol 2021;59:73. [PMID: 34368858 DOI: 10.3892/ijo.2021.5253] [Reference Citation Analysis]
5 Wang R, Bu W, Yang Y. Identification of Metabolism-Related Genes Influencing Prognosis of Multiple Myeloma Patients. J Healthc Eng 2021;2021:6574491. [PMID: 34956573 DOI: 10.1155/2021/6574491] [Reference Citation Analysis]
6 Constantinescu C, Pasca S, Zimta AA, Tat T, Rus I, Teodorescu P, Iluta S, Tanase A, Colita A, Sigurjonsson O, Einsele H, Tomuleasa C. Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies. J Clin Med 2020;9:E2903. [PMID: 32911829 DOI: 10.3390/jcm9092903] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Zhang S, Gu C, Huang L, Wu H, Shi J, Zhang Z, Zhou Y, Zhou J, Gao Y, Liu J, Leng Y, Liu X, Zhang Q, Huang L, Tong X, Young KH, Li J, Zhu H, Zhang T. The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity. Sci Rep 2022;12:10488. [PMID: 35729339 DOI: 10.1038/s41598-022-14523-0] [Reference Citation Analysis]
8 Guo R, Lu W, Zhang Y, Cao X, Jin X, Zhao M. Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting. Front Immunol 2022;13:839097. [DOI: 10.3389/fimmu.2022.839097] [Reference Citation Analysis]